What's Going On With Monopar Therapeutics Shares Friday?

Zinger Key Points
  • Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease.
  • ALXN-1840 has advanced through a Phase 3 clinical trial, successfully achieving its primary endpoint.

Monopar Therapeutics, Inc. MNPR shares are trading lower Friday after gaining on Thursday. The stock was volatile yesterday following the company’s agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 in regards to potentially treating Wilson disease.

What To Know: The drug has already advanced through a Phase 3 clinical trial, successfully achieving its primary endpoint. However, Alexion terminated the ALXN-1840 program back in 2023 based on data from Phase 2 trials and input from regulatory authorities.

Monopar will now take charge of all further development and commercialization initiatives. The company will also pay Alexion an upfront cash payment as well as equity in Monopar. Future payments will be determined by tiered royalties on net sales, as well as established regulatory and sales milestones.

“We are excited to have Alexion and AstraZeneca as partners of Monopar as, in addition to Alexion’s work in Wilson disease, AstraZeneca maintains a significant presence in the radiopharma field, in which Monopar is committed to continue growing as Monopar recently announced positive human clinical data with our novel radiopharma program,” said Andrew Cittadine, COO of Monopar.

How To Buy Monopar Stock

By now you're likely curious about how to participate in the market for Monopar Therapeutics – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

Related Link: Palantir Stock Moves Higher On L3Harris Partnership: What You Need To Know

MNPR Price Action: At the time of writing, Monopar shares are moving 38.9% lower at $19.95, according to data from Benzinga Pro.

Image: Photo by roberto-sorin for Unsplash

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!